Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 164-167

  Morrissey, Ian ^a   Seifert, Harald ^b   Canton, Rafael ^c   Nordmann, Patrice ^d   Stefani, Stefania ^e   MacGowan, Alasdair ^f   Janes, Regina ^a   Knight, Daniel ^a,g   Bonnet, R ^h   Soussy, C J ^h   Courcol, R ^h   Leclercq, R ^h   Zahar, R ^h   Poyart, C ^h   Rio, Y ^h   Pfister, W ^h   Schoerner, C ^h   Albert, F ^h   Jacobs, E ^h   Schubert, S ^h   Mutters, R ^h   Schmitz, F J ^h   Luzzaro, F ^h   Manso, E ^h   Scarparo, C ^h   Fadda, G ^h   Rossano, F ^h   Rossolini, G M ^h   Gesu, G P ^h   Landini, M P ^h   Martinez L ^h   Perez J L ^h   Gimeno, C ^h   Pascual, A ^h   Linares J ^h   Bartolome R ^h   Cisterna, R ^h   Gould, K ^h   Dryden, M ^h   Weinbren, M ^h   Swann, A ^h   Wilcox, M ^h   Moore, G ^h   Andrews, J ^h   Ashby, J ^h   Kaul, S ^h   more..

^a Quotient Bioresearch Ltd   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITY OF CATANIA   (Italy)

^f SOUTHMEAD HOSPITAL   (United Kingdom)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h NONE

Author keywords

Europe; Gram positive bacteria; Lipoglycopeptides

Indexed keywords

ORITAVANCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; ENTEROCOCCUS; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; ENTEROCOCCUS HIRAE; ENTEROCOCCUS RAFFINOSUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; STAPHYLOCOCCUS; STAPHYLOCOCCUS CAPITIS; STAPHYLOCOCCUS COHNII; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS HOMINIS; STAPHYLOCOCCUS PETTENKOFERI; STAPHYLOCOCCUS WARNERI; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; VANCOMYCIN RESISTANT ENTEROCOCCUS; WESTERN EUROPE;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; EUROPE; GLYCOPEPTIDES; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS; STREPTOCOCCUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84871183386     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks344     Document Type: Article

References (7)

1. Bouza E, Burillo A. Oritavancin: a novel lipoglyglycopeptide active against Gram-positive pathogens including multiresistant strains. Int J Antimicrob Agents 2010; 36: 401-7.
2. Saravolatz LD, Pawlak J, Johnson LB. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents 2010; 36: 69-72.
3. Mendes RE, Woosley LN, Farrell DJ et al. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. Antimicrob Agents Chemother 2012; 56: 1639-42.
4. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
5. Holliday NM, Bastulli CM, Knapp CC et al. A multi-site study comparing an 18-24h Sensititrew susceptibility system to the CLSI broth microdilution method for oritavancin using fastidious and non-fastidious Gram-positive organisms. In: Abstracts of the 108th General Meeting of the American Society for Microbiology, Boston, MA, USA, 2008. Abstract C-012. American Society for Microbiology, Washington, DC, USA.
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
7. Arhin FF, Moeck G, Draghi D et al. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against gram-positive organisms from Europe: 2005-2008. Int J Antimicrob Agents 2010; 36: 467-82.